How to cite item

Proof-of-concept assessment of metastatic sentinel node involvement by 18F-FDG positron emission tomography/computerized tomography and prediction of disease progression and survival in colorectal cancer patients with peritoneal carcinomatosis

  
@article{MAP5043,
	author = {Chi Lai Ho and Sirong Chen and Yim Lung Leung and Kam Chau Cheng and Ka Nin Wong and Shing Kee Cheung and Yuet Hung Wong},
	title = {Proof-of-concept assessment of metastatic sentinel node involvement by  18 F-FDG positron emission tomography/computerized tomography and prediction of disease progression and survival in colorectal cancer patients with peritoneal carcinomatosis},
	journal = {Mesentery and Peritoneum},
	volume = {3},
	number = {0},
	year = {2019},
	keywords = {},
	abstract = {Background: We prospectively studied the clinical significance of metastatic portal, celiac and superior mesenteric (PCS) lymph nodes with positron emission tomography/computerized tomography (PET/CT) in relation to metabolic tumor burden, prediction of disease progression and survival in patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC). 
Methods: Seventy-two patients who underwent colonic cancer resection were prospectively recruited into a 3-year longitudinal study with serial 18F-FDG PET/CT (total 310 scans) examining for PC and/or metastatic PCS nodes. PCS-positive patients were subdivided into 3 groups based on the timing of detection of PCS nodal positivity relative to the detection of peritoneal carcinomatosis; group (I) had positive nodes detected before PC; group (II) had PCS and PC detected in tandem while group (III) had nodal positivity detected after detection of PC. PC burden was quantified by a functional index, PCTLG, defined as “summation of total lesion glycolysis (TLG)” of all PC lesions on the first PET study to detect PC. Predictors for 3-year overall survival (OS) were analyzed. 
Results: PCS nodes were positive in 26/72 (36%, Groups I + II + III), negative in 46/72 (64%, Group IV) patients. Mean PCTLG was significantly higher in PCS-positive (106±73) compared with PCS-negative (26±21) patients; however, no significant difference was apparent between PCS-positive groups [PCTLGmean =104±72 (I), 138±73 (II), 50±33 (III); one-way ANOVA, P>0.05]. Patients with positive-PCS nodes or PCTLG ≥27 had significantly shorter median survival and lower 3-year OS rate (PCS+: 16 months, 7.7%; PCTLG ≥27:18 months, 14.3%). 
Conclusions: PCS nodal positivity appears to predict development of peritoneal carcinomatosis in which setting it appears to correlate with tumor burden and overall survival.  PCS nodes may represent a sentinel tier of drainage and spread in colon cancer.},
	issn = {2616-2725},	url = {https://map.amegroups.org/article/view/5043}
}